Neuropace Inc — Cash Flow (NASDAQ:NPCE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 24.6 M36.9 M19.7 M17.9 M 16.2 M Cash from investing activities 85.4 M23.8 M23.03 M8.99 M 2.2 M Cash from financing activities 102.53 M490 K8.13 M4.33 M 19.81 M Free cash flow 24.22 M36.3 M19.53 M17.59 M 15.93 M

News

LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates

NeuroPace stock price target raised to $20 from $19 at Leerink Partners

NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue

NeuroPace reports 25% revenue growth for 2025, projects steady growth

NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment

NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy

NeuroPace reports 77% seizure reduction in epilepsy device trial